Blood pressure variability (BPV) has been shown to be independently associated with cardiovascular (CV) mortality and morbidity. Patients with type 2 diabetes mellitus (T2DM) have also been shown to have increased BPV. We aimed to compare BPV in hypertensive patients with diabetes with those without diabetes. A total of 1443 hypertensive patients measured their blood pressure (BP) twice in the morning and twice before bed at home for a week. Demographic data, history of T2DM, and anti-hypertensive use were captured. Clinic BP was measured twice in the clinic. Control of BP was defined as clinic systolic BP (SBP) <140 mm Hg and home SBP < 135 mm Hg. BPV was based on home SBP measurements. A total of 362(25.1%) hypertensives had diabetes and 47.4% were male. Mean age was 62.3 ± 12.1 years. There was no difference in the mean clinic SBP in both groups (139.9 mm Hg vs 138.4 mm Hg P =.188). However, the mean morning home SBP was significantly higher and control rate lower in hypertensives with diabetes than those without (132.3 ± 15 mm Hg vs 129.7 ± 14.4 mm Hg P =.005, 39.4% vs 47.6% P =.007), respectively. Masked uncontrolled morning hypertension was higher in those with diabetes versus those without (12.8% vs 8.4%, respectively). There was no statistically significant difference in BPV between those with and without diabetes. In summary, clinic SBP was similar in hypertensives with or without diabetes. However, control of BP based on both clinic and home SBP thresholds was poorer in hypertensives with diabetes compared to those without. Masked uncontrolled morning hypertension was higher in those with diabetes than those without. There was no difference in BPV between the two groups.
|Number of pages||8|
|Journal||Journal of Clinical Hypertension|
|Publication status||Published - 2020 Mar 1|
Bibliographical noteFunding Information:
This study was supported by an Investigator Initiated Research grant from Pfizer. Omron Healthcare provided the use of computer servers to store study‐related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this manuscript.
This study was supported by an Investigator Initiated Research grant from Pfizer. Omron Healthcare provided the use of computer servers to store study-related data. The protocol for the study was developed by Jichi Medical University School of Medicine. Pfizer was not involved in the development of the protocol nor this manuscript. All procedures were conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was registered on the ClinicalTrials.gov website (NCT03096119). The authors acknowledge editorial support from Ayako Okura, editorial coordinator of Jichi Medical University School of Medicine, Japan. English language editing assistance was provided by Nicola Ryan, independent medical writer.
© 2019 Wiley Periodicals, Inc.
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine